BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: MacKenzie NE, Kowalchuk C, Agarwal SM, Costa-Dookhan KA, Caravaggio F, Gerretsen P, Chintoh A, Remington GJ, Taylor VH, Müeller DJ, Graff-Guerrero A, Hahn MK. Antipsychotics, Metabolic Adverse Effects, and Cognitive Function in Schizophrenia. Front Psychiatry 2018;9:622. [PMID: 30568606 DOI: 10.3389/fpsyt.2018.00622] [Cited by in Crossref: 47] [Cited by in F6Publishing: 62] [Article Influence: 11.8] [Reference Citation Analysis]
Number Citing Articles
1 Giordano GM, Brando F, Pezzella P, De Angelis M, Mucci A, Galderisi S. Factors influencing the outcome of integrated therapy approach in schizophrenia: A narrative review of the literature. Front Psychiatry 2022;13:970210. [DOI: 10.3389/fpsyt.2022.970210] [Reference Citation Analysis]
2 Zhao M, Qin B, Mao Y, Wang H, Wang A, Wang C. Efficacy and Safety of Low-Dose Brexpiprazole for Acute Schizophrenia: Meta-Analysis of Randomized Placebo-Controlled Trials. Neuropsychiatr Dis Treat 2022;18:1705-13. [PMID: 35979228 DOI: 10.2147/NDT.S374577] [Reference Citation Analysis]
3 Liu J, Fu L. Metabolic syndrome in patients with schizophrenia: Why should we care. Medicine (Baltimore) 2022;101:e29775. [PMID: 35960125 DOI: 10.1097/MD.0000000000029775] [Reference Citation Analysis]
4 Zhuo C, Liu W, Jiang R, Li R, Yu H, Chen G, Shan J, Zhu J, Cai Z, Lin C, Cheng L, Xu Y, Liu S, Luo Q, Jin S, Liu C, Chen J, Wang L, Yang L, Zhang Q, Li Q, Tian H, Song X; China multiple organs damage in the mental disorder (CMODMD) Group. Metabolic risk factors of cognitive impairment in young women with major psychiatric disorder. Front Psychiatry 2022;13:880031. [DOI: 10.3389/fpsyt.2022.880031] [Reference Citation Analysis]
5 Wang X, Kou X, Meng X, Yu J. Effects of a virtual reality serious game training program on the cognitive function of people diagnosed with schizophrenia: A randomized controlled trial. Front Psychiatry 2022;13:952828. [DOI: 10.3389/fpsyt.2022.952828] [Reference Citation Analysis]
6 Buck SA, Quincy Erickson-Oberg M, Logan RW, Freyberg Z. Relevance of interactions between dopamine and glutamate neurotransmission in schizophrenia. Mol Psychiatry 2022. [PMID: 35681081 DOI: 10.1038/s41380-022-01649-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Wang C, Chong Y, Zhang J, Cao Y, Wang Y. The Efficacy of Extended Metacognitive Training on Neurocognitive Function in Schizophrenia: A Randomized Controlled Trial. Brain Sci 2022;12:413. [PMID: 35326369 DOI: 10.3390/brainsci12030413] [Reference Citation Analysis]
8 Henkel ND, Wu X, O'Donovan SM, Devine EA, Jiron JM, Rowland LM, Sarnyai Z, Ramsey AJ, Wen Z, Hahn MK, McCullumsmith RE. Schizophrenia: a disorder of broken brain bioenergetics. Mol Psychiatry 2022. [PMID: 35264726 DOI: 10.1038/s41380-022-01494-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
9 Scheffler F, Phahladira L, Hendrikse CB, du Plessis S, Asmal L, Luckhoff HK, Smit AM, Olivier MR, Emsley R. The associations of cannabis and methamphetamine use with cognitive performance over the first 2 years of treatment in schizophrenia spectrum disorders. Early Interv Psychiatry 2022. [PMID: 35108745 DOI: 10.1111/eip.13272] [Reference Citation Analysis]
10 Bagheri F, Safari A, Namavar MR. Effect of dimethyl fumarate on the changes in the medial prefrontal cortex structure and behavior in the poly(I:C)-induced maternal immune activation model of schizophrenia in the male mice. Behav Brain Res 2022;417:113581. [PMID: 34530042 DOI: 10.1016/j.bbr.2021.113581] [Reference Citation Analysis]
11 Rosen AS, King LC, Kinney DI, Nitch SR, Glassmire DM. Are TOPF and WRAT WR Interchangeable Measures among Psychiatric Inpatients? Arch Clin Neuropsychol 2022:acab098. [PMID: 35034118 DOI: 10.1093/arclin/acab098] [Reference Citation Analysis]
12 Choi KM, Kim JY, Kim YW, Han JW, Im CH, Lee SH. Comparative analysis of default mode networks in major psychiatric disorders using resting-state EEG. Sci Rep 2021;11:22007. [PMID: 34759276 DOI: 10.1038/s41598-021-00975-3] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
13 Agarwal SM, Vernon AC, Venkatasubramanian G, Hahn MK. Editorial: Cardiovascular and Physical Health in Severe Mental Illness. Front Psychiatry 2021;12:760250. [PMID: 34650460 DOI: 10.3389/fpsyt.2021.760250] [Reference Citation Analysis]
14 Lee M, Fatouros-Bergman H, Plavén-Sigray P, Ikonen Victorsson P, Sellgren CM, Erhardt S, Flyckt L, Farde L, Cervenka S. No association between cortical dopamine D2 receptor availability and cognition in antipsychotic-naive first-episode psychosis. NPJ Schizophr 2021;7:46. [PMID: 34548499 DOI: 10.1038/s41537-021-00176-x] [Reference Citation Analysis]
15 Alfimova MV, Kondratyev NV, Golov AK, Kaleda VG, Abramova LI, Golimbet VE. Relationship between DNA Methylation within the YJEFN3 Gene and Cognitive Deficit in Schizophrenia Spectrum Disorders. Russ J Genet 2021;57:1092-9. [DOI: 10.1134/s1022795421080019] [Reference Citation Analysis]
16 Syed AB, Brašić JR. The role of lumateperone in the treatment of schizophrenia. Ther Adv Psychopharmacol 2021;11:20451253211034019. [PMID: 34377435 DOI: 10.1177/20451253211034019] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
17 Li W, Liu F, Liu R, Zhou X, Li G, Xiao S. APOE E4 is associated with hyperlipidemia and obesity in elderly schizophrenic patients. Sci Rep 2021;11:14818. [PMID: 34285334 DOI: 10.1038/s41598-021-94381-4] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
18 Flintoff J, Kesby JP, Siskind D, Burne TH. Treating cognitive impairment in schizophrenia with GLP-1RAs: an overview of their therapeutic potential. Expert Opin Investig Drugs 2021;30:877-91. [PMID: 34213981 DOI: 10.1080/13543784.2021.1951702] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
19 Hsu MC, Lee SC, Ouyang WC. Use of Charlson Comorbidity Index and Nomogram to Predict Mortality in Elderly Patients with Late-Life Schizophrenia. Healthcare (Basel) 2021;9:783. [PMID: 34206232 DOI: 10.3390/healthcare9070783] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
20 Jiang CG, Wang J, Liu XH, Xue YL, Zhou ZH. The Neural Correlates of Effortful Cognitive Processing Deficits in Schizophrenia: An ERP Study. Front Hum Neurosci 2021;15:664008. [PMID: 34122029 DOI: 10.3389/fnhum.2021.664008] [Reference Citation Analysis]
21 Granger KT, Ferrar J, Caswell S, Haselgrove M, Moran PM, Attwood A, Barnett JH. Effects of 7.5% Carbon Dioxide and Nicotine Administration on Latent Inhibition. Front Psychiatry 2021;12:582745. [PMID: 33935819 DOI: 10.3389/fpsyt.2021.582745] [Reference Citation Analysis]
22 Klaus F, Mitchell K, Liou SC, Eyler LT, Nguyen TT. Chemokine MCP1 is associated with cognitive flexibility in schizophrenia: A preliminary analysis. J Psychiatr Res 2021;138:139-45. [PMID: 33852994 DOI: 10.1016/j.jpsychires.2021.04.007] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
23 Sahpolat M, Ayar D, Ari M, Karaman MA. Elevated Monocyte to High-density Lipoprotein Ratios as an Inflammation Markers for Schizophrenia Patients. Clin Psychopharmacol Neurosci 2021;19:112-6. [PMID: 33508794 DOI: 10.9758/cpn.2021.19.1.112] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
24 Ruiz-Sánchez E, Jiménez-Genchi J, Alcántara-Flores YM, Castañeda-González CJ, Aviña-Cervantes CL, Yescas P, Del Socorro González-Valadez M, Martínez-Rodríguez N, Ríos-Ortiz A, González-González M, López-Navarro ME, Rojas P. Working memory deficits in schizophrenia are associated with the rs34884856 variant and expression levels of the NR4A2 gene in a sample Mexican population: a case control study. BMC Psychiatry 2021;21:86. [PMID: 33563249 DOI: 10.1186/s12888-021-03081-w] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
25 Raudeberg R, Karr JE, Iverson GL, Hammar Å. Examining the repeatable battery for the assessment of neuropsychological status validity indices in people with schizophrenia spectrum disorders. Clin Neuropsychol 2021;:1-18. [PMID: 33522847 DOI: 10.1080/13854046.2021.1876169] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
26 Prestwood TR, Asgariroozbehani R, Wu S, Agarwal SM, Logan RW, Ballon JS, Hahn MK, Freyberg Z. Roles of inflammation in intrinsic pathophysiology and antipsychotic drug-induced metabolic disturbances of schizophrenia. Behav Brain Res 2021;402:113101. [PMID: 33453341 DOI: 10.1016/j.bbr.2020.113101] [Cited by in Crossref: 2] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
27 Zhang J, Cheng X, Zhang H, Xu P, Jin P, Ke X. Analysis of the status of drug treatment in 746 inpatients with early-onset schizophrenia in China: a retrospective study. BMC Psychiatry 2021;21:10. [PMID: 33413200 DOI: 10.1186/s12888-020-02962-w] [Reference Citation Analysis]
28 Jamilian H, Ghaderi A. The Effects of Probiotic and Selenium Co-supplementation on Clinical and Metabolic Scales in Chronic Schizophrenia: a Randomized, Double-blind, Placebo-Controlled Trial. Biol Trace Elem Res 2021. [PMID: 33409919 DOI: 10.1007/s12011-020-02572-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
29 Kumar V, Nichenmetla S, Chhabra H, Sreeraj VS, Rao NP, Kesavan M, Varambally S, Venkatasubramanian G, Gangadhar BN. Prefrontal cortex activation during working memory task in schizophrenia: A fNIRS study. Asian J Psychiatr 2021;56:102507. [PMID: 33388563 DOI: 10.1016/j.ajp.2020.102507] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
30 Stogios N, Smith E, Asgariroozbehani R, Hamel L, Gdanski A, Selby P, Sockalingam S, Graff-Guerrero A, Taylor VH, Agarwal SM, Hahn MK. Exploring Patterns of Disturbed Eating in Psychosis: A Scoping Review. Nutrients 2020;12:E3883. [PMID: 33353080 DOI: 10.3390/nu12123883] [Cited by in Crossref: 3] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
31 Li S, Chen D, Xiu M, Li J, Zhang XY. Diabetes mellitus, cognitive deficits and serum BDNF levels in chronic patients with schizophrenia: A case-control study. J Psychiatr Res 2021;134:39-47. [PMID: 33360223 DOI: 10.1016/j.jpsychires.2020.12.035] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
32 Shamshoum H, Medak KD, Wright DC. Peripheral mechanisms of acute olanzapine induced metabolic dysfunction: A review of in vivo models and treatment approaches. Behav Brain Res 2021;400:113049. [PMID: 33290757 DOI: 10.1016/j.bbr.2020.113049] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
33 Fernández-Linsenbarth I, Planchuelo-Gómez Á, Díez Á, Arjona-Valladares A, de Luis R, Martín-Santiago Ó, Benito-Sánchez JA, Pérez-Laureano Á, González-Parra D, Montes-Gonzalo C, Melero-Lerma R, Morante SF, Sanz-Fuentenebro J, Gómez-Pilar J, Núñez-Novo P, Molina V. Neurobiological underpinnings of cognitive subtypes in psychoses: A cross-diagnostic cluster analysis. Schizophr Res 2021;229:102-11. [PMID: 33221149 DOI: 10.1016/j.schres.2020.11.013] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
34 Maas DA, Martens MB, Priovoulos N, Zuure WA, Homberg JR, Nait-Oumesmar B, Martens GJM. Key role for lipids in cognitive symptoms of schizophrenia. Transl Psychiatry 2020;10:399. [PMID: 33184259 DOI: 10.1038/s41398-020-01084-x] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
35 Bang-Kittilsen G, Egeland J, Holmen TL, Bigseth TT, Andersen E, Mordal J, Ulleberg P, Engh JA. High-intensity interval training and active video gaming improve neurocognition in schizophrenia: a randomized controlled trial. Eur Arch Psychiatry Clin Neurosci 2021;271:339-53. [PMID: 33156372 DOI: 10.1007/s00406-020-01200-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
36 El Abdellati K, De Picker L, Morrens M. Antipsychotic Treatment Failure: A Systematic Review on Risk Factors and Interventions for Treatment Adherence in Psychosis. Front Neurosci 2020;14:531763. [PMID: 33162877 DOI: 10.3389/fnins.2020.531763] [Cited by in Crossref: 4] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
37 Han YL, Dai ZP, Ridwan MC, Lin PH, Zhou HL, Wang HF, Yao ZJ, Lu Q. Connectivity of the Frontal Cortical Oscillatory Dynamics Underlying Inhibitory Control During a Go/No-Go Task as a Predictive Biomarker in Major Depression. Front Psychiatry 2020;11:707. [PMID: 32848905 DOI: 10.3389/fpsyt.2020.00707] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
38 Noel J, Viswanathan SA, Kuruvilla A. Nature and Correlates of Executive Dysfunction in Schizophrenia: An Exploratory Study. Indian J Psychol Med 2021;43:16-23. [PMID: 34349302 DOI: 10.1177/0253717620929494] [Reference Citation Analysis]
39 Jena M, Mishra A, Mishra BR, Nath S, Maiti R. Effect of lurasidone versus olanzapine on cardiometabolic parameters in unmedicated patients with schizophrenia: a randomized controlled trial. Psychopharmacology (Berl) 2020;237:3471-80. [PMID: 32740676 DOI: 10.1007/s00213-020-05628-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
40 Poddar I, Callahan PM, Hernandez CM, Pillai A, Yang X, Bartlett MG, Terry AV Jr. Oral quetiapine treatment results in time-dependent alterations of recognition memory and brain-derived neurotrophic factor-related signaling molecules in the hippocampus of rats. Pharmacol Biochem Behav 2020;197:172999. [PMID: 32702397 DOI: 10.1016/j.pbb.2020.172999] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
41 Doménech-Matamoros P. Influence of the use of atypical antipsychotics in metabolic syndrome. Rev Esp Sanid Penit 2020;22:80-6. [PMID: 32697278 DOI: 10.18176/resp.00014] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
42 Ferguson B, Delevich K. Mediodorsal Thalamus and Prefrontal Cortex: Specialized Partners in Cognitive Control. J Neurosci 2020;40:5515-7. [PMID: 32669402 DOI: 10.1523/JNEUROSCI.0820-20.2020] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
43 Seo DE, Kim S, Park BJ. Signals of Adverse Drug Reactions of Paliperidone Compared to Other Atypical Antipsychotics Using the Korean Adverse Event Reporting System Database. Clin Drug Investig 2020;40:873-81. [PMID: 32648200 DOI: 10.1007/s40261-020-00945-z] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
44 Lamichhane S, Dickens AM, Sen P, Laurikainen H, Borgan F, Suvisaari J, Hyötyläinen T, Howes O, Hietala J, Orešič M. Association Between Circulating Lipids and Future Weight Gain in Individuals With an At-Risk Mental State and in First-Episode Psychosis. Schizophr Bull 2021;47:160-9. [PMID: 32609372 DOI: 10.1093/schbul/sbaa087] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
45 Conn KA, Burne THJ, Kesby JP. Subcortical Dopamine and Cognition in Schizophrenia: Looking Beyond Psychosis in Preclinical Models. Front Neurosci 2020;14:542. [PMID: 32655348 DOI: 10.3389/fnins.2020.00542] [Cited by in Crossref: 6] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
46 Bakker G, Vingerhoets C, Bloemen OJN, Sahakian BJ, Booij J, Caan MWA, van Amelsvoort TAMJ. The muscarinic M1 receptor modulates associative learning and memory in psychotic disorders. Neuroimage Clin 2020;27:102278. [PMID: 32563036 DOI: 10.1016/j.nicl.2020.102278] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
47 Kaczor AA, Targowska-Duda KM, Silva AG, Kondej M, Biała G, Castro M. N-(2-Hydroxyphenyl)-1-[3-(2-oxo-2,3-dihydro-1H- benzimidazol-1-yl)propyl]piperidine-4-Carboxamide (D2AAK4), a Multi-Target Ligand of Aminergic GPCRs, as a Potential Antipsychotic. Biomolecules 2020;10:E349. [PMID: 32102432 DOI: 10.3390/biom10020349] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
48 Rotella F, Cassioli E, Calderani E, Lazzeretti L, Ragghianti B, Ricca V, Mannucci E. Long-term metabolic and cardiovascular effects of antipsychotic drugs. A meta-analysis of randomized controlled trials. Eur Neuropsychopharmacol 2020;32:56-65. [PMID: 31917068 DOI: 10.1016/j.euroneuro.2019.12.118] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
49 Andiné P, Bergman H. Focus on Brain Health to Improve Care, Treatment, and Rehabilitation in Forensic Psychiatry. Front Psychiatry 2019;10:840. [PMID: 31849721 DOI: 10.3389/fpsyt.2019.00840] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
50 Fakhfouri G, Rahimian R, Dyhrfjeld-Johnsen J, Zirak MR, Beaulieu JM. 5-HT3 Receptor Antagonists in Neurologic and Neuropsychiatric Disorders: The Iceberg Still Lies beneath the Surface. Pharmacol Rev 2019;71:383-412. [PMID: 31243157 DOI: 10.1124/pr.118.015487] [Cited by in Crossref: 29] [Cited by in F6Publishing: 32] [Article Influence: 9.7] [Reference Citation Analysis]
51 Saoud M, Saeed M, Patel S, Mador MJ. Positive Airway Pressure Adherence in Patients with Obstructive Sleep Apnea with Schizophrenia. Lung 2020;198:181-5. [PMID: 31822995 DOI: 10.1007/s00408-019-00302-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
52 Tian Y, Liu D, Wang D, Wang J, Xu H, Dai Q, Andriescue EC, Wu HE, Xiu M, Chen D, Wang L, Chen Y, Yang R, Wu A, Wei CW, Zhang X. Obesity in Chinese patients with chronic schizophrenia: Prevalence, clinical correlates and relationship with cognitive deficits. Schizophr Res 2020;215:270-6. [PMID: 31653580 DOI: 10.1016/j.schres.2019.10.017] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.7] [Reference Citation Analysis]
53 Zádor F, Nagy-Grócz G, Kekesi G, Dvorácskó S, Szűcs E, Tömböly C, Horvath G, Benyhe S, Vécsei L. Kynurenines and the Endocannabinoid System in Schizophrenia: Common Points and Potential Interactions. Molecules 2019;24:E3709. [PMID: 31619006 DOI: 10.3390/molecules24203709] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
54 Marteene W, Winckel K, Hollingworth S, Kisely S, Gallagher E, Hahn M, Ebdrup BH, Firth J, Siskind D. Strategies to counter antipsychotic-associated weight gain in patients with schizophrenia. Expert Opin Drug Saf 2019;18:1149-60. [PMID: 31564170 DOI: 10.1080/14740338.2019.1674809] [Cited by in Crossref: 16] [Cited by in F6Publishing: 25] [Article Influence: 5.3] [Reference Citation Analysis]
55 Chen H, Xu J, Mao Y, Sun L, Sun Y, Zhou Y. Positive Coping and Resilience as Mediators Between Negative Symptoms and Disability Among Patients With Schizophrenia. Front Psychiatry 2019;10:641. [PMID: 31551832 DOI: 10.3389/fpsyt.2019.00641] [Cited by in Crossref: 7] [Cited by in F6Publishing: 19] [Article Influence: 2.3] [Reference Citation Analysis]
56 Kraal AZ, Moll AC, Arvanitis NR, Ward KM, Dougherty RJ, Grove TB, Burghardt KJ, Ellingrod VL. Metabolic syndrome is negatively associated with cognition among endothelial nitric oxide synthase (eNOS)- 786C carriers in schizophrenia-spectrum disorders. J Psychiatr Res 2019;117:142-7. [PMID: 31421598 DOI: 10.1016/j.jpsychires.2019.07.006] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
57 Rahimian R, Fakhfouri G, Zirak MR. Pros and cons of 5-HT3 receptor antagonists in neuropsychiatric diseases. Biomed Pharmacother 2019;118:109301. [PMID: 31402188 DOI: 10.1016/j.biopha.2019.109301] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
58 Fang X, Wang Y, Chen Y, Ren J, Zhang C. Association between IL-6 and metabolic syndrome in schizophrenia patients treated with second-generation antipsychotics. Neuropsychiatr Dis Treat 2019;15:2161-70. [PMID: 31534339 DOI: 10.2147/NDT.S202159] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
59 Agarwal SM, Kowalchuk C, Castellani L, Costa-Dookhan KA, Caravaggio F, Asgariroozbehani R, Chintoh A, Graff-Guerrero A, Hahn M. Brain insulin action: Implications for the treatment of schizophrenia. Neuropharmacology 2020;168:107655. [PMID: 31152767 DOI: 10.1016/j.neuropharm.2019.05.032] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
60 Grover S, R P, Sahoo S, Gopal S, Nehra R, Ganesh A, Raghavan V, Sankaranarayan A. Relationship of metabolic syndrome and neurocognitive deficits in patients with schizophrenia. Psychiatry Res 2019;278:56-64. [PMID: 31146142 DOI: 10.1016/j.psychres.2019.05.023] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
61 Gjerde PB, Simonsen CE, Lagerberg TV, Steen NE, Ueland T, Andreassen OA, Steen VM, Melle I. Improvement in verbal learning over the first year of antipsychotic treatment is associated with serum HDL levels in a cohort of first episode psychosis patients. Eur Arch Psychiatry Clin Neurosci 2020;270:49-58. [PMID: 31028479 DOI: 10.1007/s00406-019-01017-w] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
62 Yun J, Lee JS, Kang SH, Nam B, Lee SJ, Lee S, Choi J, Kim C, Chung Y. Korean Treatment Guideline on Pharmacotherapy of Co-existing Symptoms and Antipsychotics-related Side Effects in Patients with Schizophrenia. Korean J Schizophr Res 2019;22:21. [DOI: 10.16946/kjsr.2019.22.2.21] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]